3D Global Biotech Inc.

Taipei Exchange 6808.TWO

3D Global Biotech Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -75.66

3D Global Biotech Inc. Price to Earnings Ratio (P/E) is -75.66 on January 14, 2025, a -50.53% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • 3D Global Biotech Inc. 52-week high Price to Earnings Ratio (P/E) is -37.03 on August 05, 2024, which is 51.06% above the current Price to Earnings Ratio (P/E).
  • 3D Global Biotech Inc. 52-week low Price to Earnings Ratio (P/E) is -87.70 on January 02, 2025, which is -15.90% below the current Price to Earnings Ratio (P/E).
  • 3D Global Biotech Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -50.21.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
Loading...
Taipei Exchange: 6808.TWO

3D Global Biotech Inc.

CEO Ruiwen Huang
IPO Date Dec. 25, 2020
Location
Headquarters No.99, Xintai 5th Road
Employees 33
Sector Health Care
Industries
Description

3D Global Biotech Inc. develops medical materials for human body reconstruction in China. It uses cell culture systems, 3D printing technology, and bio-inks hydrogel as the basis to develop and produce customized autologous cell-based medical products. The company develops human tissue and organ reconstruction platforms; develops customized and personalized medical equipment; and conducts professional research. It offers artificial bone substitute, skull fixation system, biological dressings, bio inks, and bioprinting equipment, as well as orthopedic, tooth and jaw, and skull reconstruction products, and scalp care products. It serves medical centers, research institutions, and companies and distributors to establish an interdisciplinary alliance encompassing industry, government, academia, research, and medicine. The company was founded in 2014 and is based in New Taipei City, China.

StockViz Staff

January 15, 2025

Any question? Send us an email